Charnwood Molecular is celebrating after being announced as one of just three finalists in the “Most Impactful UK Deal” category.
The nominated deal was the recent acquisition by Charnwood Molecular of Aurelia Bioscience, the specialist that provides services in biological assay development and biological screening.
CEO of Charnwood Molecular, Steve Allin, commented: “We are proud to welcome the Aurelia Bioscience team into our company. Gary Allenby, Kathy Dodgson and their team have built an outstanding reputation for scientific rigour and excellence - values that are deeply rooted in our own business culture - and this acquisition represents another key piece in our strategic plan to become the provider of choice for integrated drug discovery and development services within the global life sciences sector.”
The 13th Annual OBN Awards remains the life sciences industry’s most highly regarded awards event. The winners of the 2021 awards will be announced on 25th November at the Ashmolean Museum in Oxford.